Acarbose
InterventionApproved 19953 papers2 findingsPubChem 9811704MeSH D020909
- Animals1
- Model organisms1
Mouse lifespan
NIA ITPOutcomes
1Lifespan
downin A. domesticus1upin reviews1HR 2.92–3.03Very low certainty
2 studies
Lifespan
downin A. domesticus1upin reviews1HR 2.92–3.03Very low certainty
Acarbose extends lifespan.
Reviewin secondary trial analyses and preclinical longevity models
Beyond Diabetes: Continuous Glucose Monitoring as a Candidate Precision Tool for Cardiovascular Prevention and Healthy Longevity-A Hypothesis-Generating Narrative Review · Medicina (Kaunas, Lithuania) · 6 Aug 2026
Acarbose shortens lifespan in A. domesticus (HR = 2.92 to 3.03, P's < 0.05).
“and reduced by acarbose in females (HR = 2.92 to 3.03, P’s < 0.05).”
Model organismspost-treatment survival after 2-week intermittent dosing2-weekfemales
The house cricket (Acheta domesticus) as a scalable invertebrate model for gerotherapeutic testing · GSA 2025 abstract · 31 Dec 2025
Trials
49Approved
6 Sep 1995 · Discontinued
In trials
Phase 4 · Results posted · 28 trials
Phase 4 · Results posted · 8 trials
Glucose Intolerance
Phase 4 · Completed · 4 trials
Phase 4 · Results posted · 3 trials
Phase 4 · Completed · 3 trials
Phase 4 · Terminated · 2 trials
All 21Fewer
Phase 4 · Completed · 2 trials
Phase 4 · Completed · 1 trial
Phase 4 · Completed · 1 trial
Phase 4 · Terminated · 1 trial
Phase 3 · Results posted · 1 trial
Phase 3 · Results posted · 1 trial
Phase 3 · Results posted · 1 trial
Phase 3 · Completed · 1 trial
Aging
Phase 2 · Results posted · 2 trials
Non-alcoholic fatty liver disease
Phase 2 · Terminated · 1 trial
Phase 1/2 · Completed · 1 trial
Phase 1 · Completed · 1 trial
Phase 1 · Completed · 1 trial
Phase 1 · Completed · 1 trial
Early phase 1 · Status unknown · 1 trial
Stopped
NCT02072096 · Terminated · Type 2 diabetes
The trial was terminated per protocol because of lack of feasibility.
NCT02953093 · Terminated · Aging
Upon review it was determined that the study terminated early due to lack of funding. Study never reached enrollment target and was administratively closed out by the Albert Einstein College of Medicine IRB.
NCT00677521 · Terminated · Non-alcoholic fatty liver disease
poor recruitment and no student currently interested in working on this project.
Trial sponsors
Company7 trialsPhase 4746 people
Company2 trialsPhase 45,950 people
Company2 trialsPhase 41,276 people
Company1 trialPhase 4192 people
Company1 trialPhase 415 people
Company1 trialPhase 3220 people
Company1 trialPhase 3113 people
Company2 trialsPhase 2195 people